Fintech PR
Global Bakery Premixes Market Worth USD 1.65 Billion by 2025: Hexa Research
Reading Time: 3 minutes
The global bakery premixes market was estimated at USD 1.18 billion in 2017 and is expected to grow at a CAGR of 4.27% from 2017 to 2025, to reach a value of USD 1.65 billion by 2025. The market growth is attributed to the increasing demand for customized bakery products among the consumers especially in the developed and developing countries.
The U.S., UK, Germany, China, Italy, and Russia, are the major consumers of bread and bakery products. The continuous demand and popularity of such products is expected to drive the demand for the baking premixes market. Use of these premixes has resulted in effortless baking of a lot of varieties of bread and bakery products. The market is gaining an increasing traction especially among the manufacturers due to the reliable and hassle-free production.
The U.S. bread and bakery products market is gaining an increasing momentum primarily driven by the spurring demand for bread products containing high fiber such as wholegrain, or diet and healthy biscuits and cookies. Consumers’ shift towards healthy lifestyle practices will boost the demand for these kind of products, which in turn is expected to drive the production of premix ingredients to meet the requirements.
The average spending of the U.S. households on bakery products per household is expected to increase to USD 383.75 by 2021, wherein most of this expenditure will be on bread products, followed by cakes and cupcakes. This scenario is likely to offer lucrative opportunities for the bakery premixes market to grow in the coming years.
Browse full research report with TOC on “Global Bakery Premixes Market Size and Forecast By Product (Complete Mix, Dough Base Mix, and Dough Concentrates) By Application (Bread and Non-Bread Products) And Trend Analysis, 2019 – 2025” at:
https://www.hexaresearch.com/research-report/bakery-premixes-market
Growing demand for various bakery products such as donuts, pies, pastries, breads, cakes and others, is expected to drive the premixes market growth. This industry is expected to continue growing over the next few years, supported by various factors such as, variety of product innovations, availability of food items at reasonable prices, rapid urbanization, busy lifestyles, and convenience of baked products. The simultaneous growth in the bakery industry is expected to impact the acceptance of premixes market to speed up the production processes.
Rising popularity of products such as whole grain, trans-fat free and multi grain along with increasing demand for flavor preferences are also expected to contribute to the growing acceptance of these premixes among the manufacturers. Increasing consumption of bread based products in India and Australia, is expected to be one of the major factors contributing to the premixes market expansion during the forecast period.
Increasing inclination towards breads, bread rolls, pastries, cakes, pies, pretzels, cookies, crackers, and tortillas is expected to result in the significant application of bakery premixes, over the forecast period. Bread is expected to continue its growth and will remain the most widely consumed bakery product worldwide, whereas pastries and cakes are expected to witness the fastest growth in the coming years.
The introduction of different flavors, rising disposable income, popularity of bakery products in Asia Pacific and Latin America will drive the demand for pastries over the forecast period. Moreover the demand for donuts will considerably increase on account of an indulgence factor and the introduction of modern chains in countries such as China, India and Brazil. These factors are expected to contribute to the prominent growth of the global bakery premixes market over the forecast period.
Key players operating in the global market include Archer Daniels Midland Company, Enhance Proteins LtdEchema Technologies LLC, Puratos, Karl Fazer Ab., Allied Mills, Swiss Bake Ingredients Pvt Ltd, Lesaffre, and Bakels Worldwide to name a few. While premixes for various bakery products such as cookies, cakes and pastries have always been popular among working women, they are now gradually becoming popular among the manufacturers too. This scenario has prompted the companies to introduce premixes for all bakery products such as puff pastries, multi-grain breads and lava cakes.
Browse related reports by Hexa Research:
- Soy Food Market – The global soy food market revenue was USD 36.67 billion in 2017 and is expected to reach USD 56.66 billion by 2025.
- Vegan Yogurt Market – The global vegan yogurt market was valued at USD 748.8 million in 2017 and is anticipated to grow at a CAGR of 16.4% from 2017 to 2025.
- Cold Pressed Juice Market – The cold pressed juice market is anticipated to witness significant growth in the coming years attributed to growing health awareness among consumers.
- Orange Juice Market – The global orange juice market is projected to witness remarkable growth in the coming years owing to changing consumer preference for healthy food products.
Hexa Research has segmented the global bakery premixes market report based on product, application and region:-
Segmentation by Product
- Complete Mix
- Dough-based Mix
- Dough Concentrates
Segmentation by Application
- Bread Products
- Non-Bread Products
Segmentation by Region
- North America
- U.S.
- Europe
- Germany
- UK
- Asia Pacific
- India
- China
- Central and South America
- Middle East and Africa
SOURCE: Hexa Research
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News6 days ago
DEMAND AT ASIAN FACTORIES RISES AT STRONGEST RATE IN OVER 2 YEARS, IMPROVING NEAR-TERM GROWTH OUTLOOK FOR MANUFACTURING WORLDWIDE: GEP GLOBAL SUPPLY CHAIN VOLATILITY INDEX
-
Latest News7 days ago
Bitrue Gears Up for 2024 Bitcoin Halving with Trading Competition
-
Latest News7 days ago
Global Airlines Appoints New Head of Finance from KPMG
-
Latest News5 days ago
“The Hainan FTP and Me”: Looking at Hainan’s Transformations
-
Latest News6 days ago
Spendesk combines procurement with spend management through Okko acquisition
-
Latest News7 days ago
BtcTurk Organizes Half Marathon in Istanbul to Celebrate Halving Period
-
Latest News4 days ago
Millions of people unite around doing good on the 18th International Good Deeds Day held yesterday worldwide
-
Latest News7 days ago
Bitget to Take Center Stage at Blockchain Life and Token2049 Dubai